F. Zanieri
University of Florence
8 Papers
10 Citations
F. Zanieri is an academic researcher from University of Florence. The author has contributed to research in topics: Protein kinase B & PI3K/AKT/mTOR pathway. The author has an hindex of 5, co-authored 8 publications.
Chat about Author
Papers
The conformational state of hERG1 channels determines integrin association, downstream signaling, and cancer progression
Andrea Becchetti,Silvia Crescioli,F. Zanieri,Giulia Petroni,Raffaella Mercatelli,Stefano Coppola,Luca Gasparoli,Massimo D'Amico,Serena Pillozzi,Olivia Crociani,Matteo Stefanini,Antonella Fiore,Laura Carraresi,Virginia Morello,Sagar S. Manoli,Maria Felice Brizzi,Davide Ricci,Mauro Rinaldi,Alessio Masi,Thomas Schmidt,Franco Quercioli,Paola Defilippi,Annarosa Arcangeli +22 more
TL;DR: Whether hERG1 promotes proliferation or metastasis in cancer cells depends on the conformation of the channel and suggests that hERG 1 inhibitors that are tailored to the channel conformation could be used to prevent different aspects of tumor progression.
Oxidative Stress in the Healthy and Wounded Hepatocyte: A Cellular Organelles Perspective
TL;DR: This review recapitulates the evolving concept of oxidative stress in the diverse cellular compartments, highlighting the principle mechanisms of oxidative Stress occurring in the healthy and wounded hepatocyte.
Liver haploinsufficiency of RuvBL1 causes hepatic insulin resistance and enhances hepatocellular carcinoma progression
Tommaso Mello,M. Materozzi,F. Zanieri,I. Simeone,Elisabetta Ceni,Oxana Bereshchenko,Simone Polvani,Mirko Tarocchi,G. Marroncini,Claus Nerlov,Daniele Guasti,Daniele Bani,Massimo Pinzani,Andrea Galli +13 more
TL;DR: A role of RuvBL1 at the intersection of liver metabolism, hepatocyte proliferation and HCC development is uncovered, providing a molecular rationale for its overexpression in liver cancer.
Switch from etanercept to efalizumab in a psoriatic patient with HCV infection: a case report.
TL;DR: Very often psoriasis is associated to other illnesses and the dermatologist has to be aware that comorbidities have to be taken in account for a successfull treatment of the disease.
8